CD19 and diffuse large B-cell lymphoma: At present, two different CD19-directed CAR T cell products have been approved for treatment of R/R DLBCL after two lines of systemic therapy, namely axicabtagene ciloleucel (Axi-cel; Yescarta) (NCT03391466, NCT03761056, NCT04002401), and tisagenlecleucel (CTL109; Kymriah) (NCT03642626) [175,176].